Browsing publications by Dr Barry King

Newcastle AuthorsTitleYear
Dr Joseph Gray
Dr Dipanker Chattopadhyay
Dr Gary Beale
Dr Gillian Patman
Dr Luca Miele
et al.
A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease2009
Dr Ellen Hatch
Elizabeth Sconce
Dr Barry King
Dr Hilary Wynne
Professor Ann Daly
et al.
Polymorphisms in genes associated with the vitamin K epoxide reductase complex do not affect warfarin dose requirement2007
Professor Ann Daly
Dr Barry King
Contribution of CYP2C9 to variability in vitamin K antagonist metabolism2006
Professor Ann Daly
Dr Barry King
Julian Leathart
Genotyping for cytochrome P450 polymorphisms2006
Dr Barry King
Dr Tayyaba Khan
Professor Farhad Kamali
Professor Ann Daly
[abstract] CYP2C9 polymorphisms and haplotypes: correlation with warfarin dose and metabolism2005
Elizabeth Sconce
Dr Tayyaba Khan
Dr Hilary Wynne
Dr Patrick Kesteven
Dr Peter Avery
et al.
[abstract] Pfizer poster communication prize - The influence of patient age, CYP2C9 genotype and height on warfarin dose requirements2005
Elizabeth Sconce
Dr Tayyaba Khan
Dr Hilary Wynne
Dr Peter Avery
Dr Barry King
et al.
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen2005
Dr Barry King
Dr Pamela MacDonald
Dr Dipanker Chattopadhyay
Dr Helen Reeves
The Kruppel-like factor 6 tumour suppressor induces apoptosis in HepG2 cells2005
Professor Farhad Kamali
Dr Tayyaba Khan
Dr Barry King
Dr Patrick Kesteven
Peter Wood
et al.
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin2004
Professor Ann Daly
Dr Barry King
CYP3A5 phenotype-genotype correlations in a British population - Response2004
12